SEC Form 4 · accession 0001209191-17-021564
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Mar 16, 2017
Accepted (ET)
Mar 17, 2017 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 16, 2017 | F | 3,171 | $19.2007 | D | 196,219 | D | |
| Common StockF2 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 3,171 shares withheld by and surrendered to the Issuer on March 16, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of 8,333 shares subject to the restricted stock award.
- F2These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.